Introduction {#Sec1}
============

Emesis is an autonomic reflex controlled by multiple neurotransmitter systems; two of the most important are the serotonin/5-hydroxytryptamine receptor 3 (5-HT~3~) and substance P/neurokinin-1 receptor (NK-1) systems \[[@CR13]\]. Blocking both the 5-HT~3~ and NK-1 neurotransmitter receptors has been demonstrated to prevent chemotherapy-induced nausea and vomiting in patients receiving chemotherapy \[[@CR6], [@CR11], [@CR12], [@CR20], [@CR29]\]. According to guidelines established by the Multinational Association for Supportive Care in Cancer \[[@CR23]\], patients who will receive a moderately emetogenic chemotherapy (MEC) regimen should receive a 5-HT~3~ receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV), while patients who will receive a MEC regimen that includes anthracycline and cyclophosphamide or a highly emetogenic chemotherapy (HEC) regimen should receive a 5-HT~3~ receptor antagonist, a corticosteroid, and an NK-1 receptor antagonist \[[@CR23], [@CR25]\].

NK-1 receptor antagonists have also shown efficacy in the treatment and prevention of postoperative nausea and vomiting (PONV), both alone and in combination with a 5-HT~3~ receptor antagonist \[[@CR7], [@CR10], [@CR28]\]. Without prophylactic antiemetics, approximately 20--30% of surgical patients experience PONV \[[@CR18], [@CR30]\], and, in the highest-risk patients, PONV may occur in up to 70--80% of cases \[[@CR1], [@CR9]\].

Casopitant, a novel NK-1 receptor antagonist, is under investigation as part of a three-drug antiemetic regimen including a 5-HT~3~ receptor antagonist and corticosteroid for patients receiving MEC or HEC. In clinical studies, casopitant is a weak to moderate inhibitor of the drug-metabolizing enzyme CYP3A (depending on dose and duration of dosing) but does not appear to have any significant impact on CYP2D6 after 50 or 100 mg single oral doses of casopitant as assessed by the CYP2D6 probe, debrisoquine (unpublished data, GlaxoSmithKline 2006).

*In vivo*, the 5-HT~3~ receptor antagonist dolasetron is rapidly reduced (half-life of less than 15 min \[[@CR17]\]) by ubiquitous carbonyl reductases to its metabolically active form, hydrodolasetron, which is largely responsible for the pharmacologic activity (\[[@CR3], [@CR8]\] and references therein). Hydrodolasetron is further metabolized by CYP2D6 with minor involvement of CYP3A4 \[[@CR26]\]. Plasma exposures of hydrodolasetron are increased approximately threefold in CYP2D6 poor metabolizers (PMs) as compared to extensive metabolizers (EMs) \[[@CR19]\]. For CYP2D6 PMs, CYP3A4 is likely to play a larger role in the clearance of hydrodolasetron, and these subjects may be more sensitive to coadministration of inhibitors of CYP3A, such as casopitant. *In vitro*, granisetron is primarily metabolized by CYP1A1 and CYP3A4 \[[@CR4], [@CR24]\] and therefore plasma levels of granisetron also may be increased when coadministered with casopitant.

The aim of this study was to assess the impact of a 3-day regimen of casopitant on the pharmacokinetics of repeat doses of oral dolasetron (as assessed by hydrodolasetron exposure) or granisetron. The pharmacokinetics of casopitant were not assessed since neither (hydro)dolasetron nor granisetron are significant inhibitors of cytochrome P450 (CYP) enzymes and are therefore unlikely to impact the clinical pharmacokinetics of casopitant to any relevant extent \[[@CR2], [@CR4]\]. In addition, acute, usually reversible, cardiac effects including QTc prolongation have been observed following dolasetron administration \[[@CR2]\]. Arrhythmias such as bradycardia have been observed with other 5-HT~3~ receptor antagonists, although to a lesser extent. Therefore, a PK interaction that may lead to increased hydrodolasetron or granisetron plasma concentrations has the potential to increase the risk of electrocardiogram (ECG) abnormalities. Therefore, this study also evaluated the potential for ECG changes following administration of dolasetron or granisetron with oral casopitant.

Subjects and methods {#Sec2}
====================

Subject population {#Sec3}
------------------

Male and female subjects of 18 to 64 years of age, body mass index of ≥19 to ≤37 kg/m^2^, and adequate organ function were eligible to enter the study. All females of childbearing potential were required to use birth control from 14 days before the first dose of study medication, throughout the study, and for 14 days after the last dose of study medication. Exclusion criteria were designed to ensure that subjects were in good health and not receiving concomitant medications that could interfere with the pharmacokinetics of study medications.

For the dolasetron cohort, subjects were eligible only if they were determined to be either CYP2D6 PMs (\*3, \*4, \*5, \*6, or \*7 homozygotes) or CYP2D6 EMs (absence or heterozygotes for \*3, \*4, \*5, \*6, or \*7 alleles and devoid of CYP2D6 gene duplication) by genotypic analysis (\[[@CR21]\] Gentris, Morrisville NC, USA). Approximately an equal number of CYP2D6 EMs and PMs were to be enrolled in the dolasetron cohort of the study.

The study protocol and informed consent documents were reviewed and approved by an institutional review board and subjects provided written consent prior to participation in the trial. All investigators were required to abide by Good Clinical Practices, International Conference on Harmonization guidelines, Declaration of Helsinki principles, and local laws and regulations.

Study design {#Sec4}
------------

This was a phase I, open-label, two-part, two-period, single-sequence study. Two cohorts of subjects received either oral dolasetron (100 mg once daily for 3 days) or oral granisetron (2 mg once daily for 3 days) alone (period 1) and then combined (period 2) with oral casopitant (150 mg day 1, 50 mg days 2 and 3). Each period was separated by a window of 5 to 14 days. During period 2, casopitant was coadministered at the same time with either dolasetron or granisetron. All doses of study medication were taken after at least a 2 h fasting period. Plasma pharmacokinetics of hydrodolasetron and granisetron were assessed on days 1 and 3 of each period with blood samples collected predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h postdose. Safety was assessed through adverse-event reporting and evaluation of clinical laboratory parameters and vital signs. In both periods, 12-lead electrocardiograms were performed on days 1 to 3 prior to administration of dolasetron or on day 1 prior to administration of granisetron.

Pharmacokinetics {#Sec5}
----------------

Human ethylenediaminetetraacetic acid plasma samples (50 μL aliquot) were analyzed for hydrodolasetron or granisetron using validated analytical methods based on protein precipitation, followed by high-performance liquid chromatography/mass spectrometry (MS)/MS analysis. For hydrodolasetron, the lower and upper limits of quantification were 1 and 1,000 ng/mL, respectively. For granisetron, the lower and upper limits of quantification were 0.1 and 100 ng/mL, respectively. Quality control (QC) samples, prepared at three different analyte concentrations and stored with study samples, were analyzed with each batch of samples against separately prepared calibration standards. For the analysis to be acceptable, no more than one third of the QC results were to deviate from the nominal concentration by more than 15%, and at least 50% of the results from each QC concentration should be within 15% of nominal. The applicable analytical runs met all predefined run acceptance criteria.

Pharmacokinetic parameters area under the curve (AUC)(0-τ) and Cmax were determined on both days 1 and 3 in periods 1 and 2 using standard non-compartmental methods (WinNonlin, version 4.1, Pharsight Corp, Mountain View, CA, USA).

Statistics {#Sec6}
----------

An estimation approach was taken to determine the magnitude of the interaction between hydrodolasetron or granisetron and casopitant. AUC and Cmax were statistically analyzed by performing an analysis of variance (ANOVA) on log(e)-transformed data in order to compute an estimate of the geometric least-square mean ratios and 90% confidence intervals (CI) for AUC(0-τ) and Cmax comparing the test treatment in period 2 (5HT~3~ + casopitant) to the reference treatment in period 1 (5HT~3~ alone). No clinically meaningful interaction effect was assumed if the 90% CI for the mean ratio was completely within the interval of 0.8 to 1.25.

For the dolasetron cohort, the ANOVA used a mixed-effects model with subject as a random effect and treatment, day, and population (CYP2D6 EM or PM) as well as all two- and three-way interactions of treatment, day, and population as fixed effects. For the granisetron cohort, the ANOVA used a mixed-effects model with subject as a random effect and treatment, day, and treatment-by-day interaction as fixed effects.

A sufficient number of subjects were enrolled to ensure that at least 12 evaluable subjects completed each part of the study. In the dolasetron arm, a minimum of six CYP2D6 PMs and six EMs were to complete the study. With the assumption that the within-subject coefficient of variation (CV) is 41%, the lower and upper bounds of the 90% CI for the ratio of the geometric means for pharmacokinetic parameters were calculated to be within 19% of the point estimates. This calculation was based on a symmetric two-tailed procedure on the log(e) scale and a type I error rate of 5% in each tail. In the granisetron arm, with the assumption of the within-subject CV of 23%, a sample size of 12 evaluable subjects, and similar analysis procedure as described above, the lower and upper bounds of the 90% CI were calculated to be within 10% of the point estimates.

Results {#Sec7}
=======

A total of 18 healthy adult subjects were enrolled in the dolasetron cohort; nine subjects were CYP2D6 EMs and nine subjects were CYP2D6 PMs. A total of 19 healthy adult subjects were enrolled in the granisetron cohort. Demographic characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Demographic characteristics of enrolled subjectsCharacteristicDolasetron cohort, *n* = 18Granisetron cohort, *n* = 19Age in years, mean (range)30.3 (21--41)41.3 (20--64)Sex, *n* (%) Female1 (6%)17 (89%) Male17 (94%)2 (11%)Height, cm (mean and range)176.6 (168--190)163.6 (156--180)Weight, kg (mean and range)88.41 (59.1--125)70.2 (54.1--98.2)BMI, kg/m^2^ (mean and range)28.25 (18.84--36.55)26.14 (21.03--35.64)Race, *n* (%) African American/African heritage3 (17%)2 (11%) White/Caucasian/European heritage15 (83%)16 (84%) Mixed race01 (5%)Genotype, *n* (%) Extensive metabolizers (EM)9 (50%)NA Poor metabolizers (PM)9 (50%)NA*NA* not applicable

Dolasetron {#Sec8}
----------

Coadministration of casopitant with dolasetron resulted in slight increases in mean hydrodolasetron AUC and Cmax on days 1 and 3, with no mean increase in exposure of more than 25% (Table [2](#Tab2){ref-type="table"}). All 90% CIs for hydrodolasetron AUC ratios were within the range of 0.8 to 1.25; however, the upper bound was exceeded for ratios of hydrodolasetron Cmax. In the CYP2D6 EM population, there were 24% and 10% mean increases in hydrodolasetron AUC on days 1 and 3, respectively, and 30% mean increases in Cmax on both days 1 and 3. CYP2D6 PMs exhibited approximately twice the exposure to hydrodolasetron as CYP2D6 EMs when dolasetron was administered alone (Fig. [1](#Fig1){ref-type="fig"}). However, after coadministration with casopitant, CYP2D6 PMs exhibited smaller changes in hydrodolasetron AUC and Cmax compared to CYP2D6 EMs. For CYP2D6 PMs, only the day 3 Cmax parameter ratio exceeded the predefined 90% CI range of 0.8 to 1.25, with a mean increase of 14%. Fig. 1Day 1 and day 3 hydrodolasetron AUC(0-τ) and Cmax when a 3-day regimen of 100 mg oral dolasetron is given alone and in combination with a 3-day oral regimen of casopitant in CYP2D6 EMs (*circles*) and CYP2D6 PMs (*triangles*)Table 2Change in hydrodolasetron and granisetron AUC and Cmax when coadministered with casopitant (ratio of dolasetron or granisetron plus casopitant to dolasetron or granisetron alone)AnalytePopulationDayAUC ratio (90% CI)Cmax ratio (90% CI)HydrodolasetronAll11.14 (1.08, 1.20)1.18 (1.06, 1.31)31.07 (1.03, 1.13)1.22 (1.10, 1.36)CYP2D6 EMs11.24 (1.15, 1.34)1.30 (1.11, 1.53)31.10 (1.02, 1.19)1.31 (1.11, 1.53)CYP2D6 PMs11.05 (0.97, 1.12)1.06 (0.92, 1.23)31.05 (0.98, 1.12)1.14 (0.99, 1.32)GranisetronAll11.08 (0.93, 1.26)1.11 (0.95, 1.29)31.00 (0.86, 1.17)1.04 (0.89, 1.22)

Granisetron {#Sec9}
-----------

Coadministration of casopitant with granisetron resulted in mean increases in granisetron AUC and Cmax of 11% or less (Table [2](#Tab2){ref-type="table"}). The day 1 90% CIs for AUC and Cmax were just outside the 0.8 to 1.25 interval, but the 90% CIs were within the interval on day 3. Results from individual subjects are illustrated in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2Day 1 and day 3 granisetron AUC(0-τ) and Cmax when a 3-day regimen of 2 mg oral granisetron is given alone and in combination with a 3-day oral regimen of casopitant

Safety {#Sec10}
------

Coadministration of casopitant and dolasetron or granisetron was well tolerated. Adverse-event frequencies are summarized in Table [3](#Tab3){ref-type="table"}. The most common adverse event was headache which occurred at a lower frequency in casopitant-containing regimens. When casopitant was coadministered with dolasetron, the adverse-event profile was similar to dolasetron administered alone. When casopitant was coadministered with granisetron, the incidence of somnolence increased and the incidence of constipation decreased compared to granisetron administered alone. All adverse events were mild or moderate in intensity, and all events resolved. There were no serious adverse events and no deaths. Changes in clinical laboratory values, vital signs, and ECGs were not clinically meaningful. Table 3Adverse events reported in two or more subjects Dolasetron, *N* = 18, *n* (%)Dolasetron + casopitant, *N* = 18, *n* (%)Granisetron, *N* = 19, *n* (%)Granisetron + casopitant, *N* = 18, *n* (%)Subjects with any adverse event5 (28%)4 (22%)11 (58%)7 (39%)Headache4 (22%)1 (6%)5 (26%)2 (11%)Somnolence1 (6%)3 (17%)05 (28%)Dizziness1 (6%)1 (6%)1 (5%)1 (6%)Constipation006 (32%)1 (6%)

Discussion {#Sec11}
==========

This study examined the potential for pharmacokinetic interactions between oral casopitant and repeat-dose oral dolasetron or granisetron using the highest oral dose of casopitant currently under investigation for the prevention of CINV, i.e., 150 mg on day 1, followed by 50 mg on days 2 and 3. An intravenous formulation of 90 mg casopitant is also under investigation; however, as oral administration results in higher gut and liver concentrations of study drug and these sites are known to have higher concentrations of CYP enzymes and thus higher potential CYP inhibition \[[@CR16]\], less significant interactions would be expected after intravenous administration of casopitant.

Clinical studies using coadministration of oral midazolam have demonstrated that casopitant results in weak to moderate inhibition of CYP3A in the oral dose range of 50 to 150 mg but no inhibition of CYP2D6 using debrisoquine as a probe with single oral doses up to 100 mg and there is no *in vitro* evidence that casopitant is a significant inhibitor of CYP1A enzymes (unpublished data, GlaxoSmithKline).

The major circulating active metabolite of dolasetron, hydrodolasetron, is metabolized by CYP2D6 and, to a lesser extent, by CYP3A4. The current study showed that coadministration of dolasetron with a 3-day regimen of casopitant resulted in no clinically relevant change in the exposure of hydrodolasetron. The largest observed changes were a 14% increase in hydrodolasetron AUC on day 1 and 18% and 22% increases in hydrodolasetron Cmax on days 1 and 3, respectively. These changes are not considered clinically relevant, were not associated with any increase in adverse events, and were within the same range of within-subject variability for dolasetron exposure (41% as described in "[Statistics](#Sec6){ref-type="sec"}").

CYP2D6 is responsible for a large proportion of hydrodolasetron clearance and is polymorphically expressed. CYP2D6 PMs had only approximately twofold higher hydrodolasetron exposure than CYP2D6 EMs in this study (Fig. [1](#Fig1){ref-type="fig"}). There is a theoretical potential for increased pharmacokinetic interaction between casopitant and hydrodolasetron in CYP2D6 PMs as CYP3A4 is likely to comprise a larger proportion of hydrodolasetron clearance in these subjects. The majority of the Caucasian population (70%) would be classified as CYP2D6 EMs, requiring just one copy of a functional CYP2D6 allele (\*1 or \*2); however, 51% of the African American population are EMs and 35% would be classified as reduced function or intermediate metabolizers. The frequency of PM status (non-functional alleles) is 5--10% in Caucasian populations and 15% in African Americans \[[@CR5]\].

The statistical analysis of hydrodolasetron exposure in CYP2D6 EMs and PMs (Table [2](#Tab2){ref-type="table"}) shows that CYP2D6 PMs did not exhibit significant increases in hydrodolasetron exposure when dolasetron was coadministered with casopitant. Likewise in CYP2D6 EMs, although hydrodolasetron exposure was increased 10% (AUC) to 31% (Cmax), these increases were not considered clinically relevant since the slightly higher hydrodolasetron exposures in CYP2D6 EMs in the presence of casopitant were still substantially lower than those observed in CYP2D6 PMs with dolasetron alone. While the observed level of interaction observed in EMs and PMs was not as anticipated, the changes in AUC in both groups were small (\<25%) and are likely to reflect the small subject numbers in each population, subject to subject variability and the ability of hydrodolasetron to be metabolized by multiple CYP enzymes.

When granisetron, which is primarily metabolized by CYP1A1 and CYP3A4, was coadministered with casopitant, changes in exposure were minor (mean increases in exposure of less than or equal to 11%) and were not associated with any change in the safety or adverse-event profile of granisetron that would not be considered clinically important given that the within-subject variability for granisetron exposure is approximately 23% (see "[Statistics](#Sec6){ref-type="sec"}").

Coadministration of casopitant and dolasetron or granisetron was well tolerated. All adverse events were mild or moderate in intensity, and all events resolved. The ECG effects of hydrodolasetron are dose dependent and were reported to be observed at single doses greater than 200 mg \[[@CR19]\]. Since the recommended oral dose of dolasetron of 100 mg was utilized in the present study, increase in plasma concentration of up to twofold or 100% (equal to a 200-mg dose) can be considered clinically unimportant for the 100-mg dose. The maximum increase in Cmax seen in the present study was only 31%. Moreover, no apparent differences in cardiac function (QTc, bradycardia) occurred when either dolasetron or granisetron was coadministered with casopitant. Similarly, no effect on cardiac function of casopitant coadministered with the serotonin antagonist ondansetron was recently reported \[[@CR15]\]. Further, Li et al. \[[@CR19]\] have reported that there is no effect of a similar NK-1 receptor antagonist, aprepitant, on the PK and cardiac safety profile of hydrodolasetron in CYP2D6 EMs or PMs. Consequently, these findings, coupled with no clinically important increase in hydrodolasetron or granisetron exposure in the presence of casopitant, suggest that casopitant is unlikely to increase the potential for either of these drugs to elicit life-threatening arrhythmias. Similar insignificant changes in ondansetron exposure and safety have been observed in another drug--drug interaction study with casopitant \[[@CR14]\]. While the majority of subjects in the dolasetron cohort were male and the majority in the granisetron cohort were female, previous unpublished studies have shown that casopitant pharmacokinetics is similar in male and female subjects. Casopitant, therefore, would be expected to have a similar inhibitory potential on CYP3A-metabolizing enzymes and result in similar observations to those observed in the current study.

Given that palonosetron is also metabolized by the same mixed CYP enzymes as other 5-HT~3~ receptor antagonists (CYP2D6, 3A4, 1A2) and is administered intravenously \[[@CR22]\], no drug--drug interaction of clinical relevance between casopitant and palonosetron would be anticipated. Indeed, a study investigating the concomitant administration of another NK-1 receptor antagonist, aprepitant, and IV palonosetron concluded that no dosage adjustment of either agent was needed when administered together \[[@CR27]\]. The current study demonstrates that casopitant coadministered with the 5-HT~3~ receptor antagonists dolasetron or granisetron does not result in clinically relevant changes in the pharmacokinetics or safety of these agents and that these combinations may be used in antiemetic regimens for the prevention of PONV or CINV.
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